Market closed

Verve Therapeutics/$VERV

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Verve Therapeutics

Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.

Ticker

$VERV
Trading on

Industry

Biotechnology

Employees

274

VERV Metrics

BasicAdvanced
$596M
-
-$2.35
1.78
-
$596M
1.78
$16.03
$4.31
1.4M
12.649
12.294
12.067
14.184
-20.41%
-36.36%
17.583
1.21
1.21
-3.522
174.98%
-24.77%
-19.39%

What the Analysts think about VERV

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Verve Therapeutics stock.

VERV Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

VERV Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $VERV

$
Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs

What’s the current market cap for Verve Therapeutics stock?

Verve Therapeutics (VERV) has a market cap of $596M as of March 11, 2025.

What is the P/E ratio for Verve Therapeutics stock?

The price to earnings (P/E) ratio for Verve Therapeutics (VERV) stock is 0 as of March 11, 2025.

Does Verve Therapeutics stock pay dividends?

No, Verve Therapeutics (VERV) stock does not pay dividends to its shareholders as of March 11, 2025.

When is the next Verve Therapeutics dividend payment date?

Verve Therapeutics (VERV) stock does not pay dividends to its shareholders.

What is the beta indicator for Verve Therapeutics?

Verve Therapeutics (VERV) has a beta rating of 1.78. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.